Intec Pharma (NASDAQ:NTEC) received a $15.00 price target from equities researchers at Oppenheimer in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective points to a potential upside of 185.71% from the company’s previous close.
A number of other research firms have also recently weighed in on NTEC. Zacks Investment Research cut shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Intec Pharma in a research report on Monday, March 12th. Maxim Group boosted their price target on shares of Intec Pharma from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Monday, March 26th. Finally, Ladenburg Thalmann initiated coverage on shares of Intec Pharma in a research report on Wednesday, February 28th. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $12.67.
NASDAQ NTEC opened at $5.25 on Wednesday. The stock has a market capitalization of $166.88, a P/E ratio of -3.18 and a beta of 1.26. Intec Pharma has a twelve month low of $4.80 and a twelve month high of $9.80.
A number of large investors have recently added to or reduced their stakes in NTEC. Meitav Dash Investments Ltd. acquired a new position in Intec Pharma in the fourth quarter valued at about $8,607,000. Millennium Management LLC acquired a new position in Intec Pharma in the fourth quarter valued at about $1,392,000. Pura Vida Investments LLC acquired a new position in Intec Pharma in the third quarter valued at about $895,000. Renaissance Technologies LLC boosted its position in Intec Pharma by 66.0% in the fourth quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock valued at $688,000 after buying an additional 53,100 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Intec Pharma by 59.2% in the fourth quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 42,867 shares in the last quarter. Hedge funds and other institutional investors own 41.39% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.